Holders — by stockHoldings — by fund
Octagon Capital Advisors LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001839435
$1.11B
disclosed book value
27
positions
16.1%
largest position share
Positions, as of 2026-06-30
top 27 of 27 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | DNTHDIANTHUS THERAPEUTICS INC | 1.8M | $179.5M | 16.1% |
| 2 | DFTXDEFINIUM THERAPEUTICS INC | 3.0M | $138.8M | 12.5% |
| 3 | ABVXABIVAX SA | 993,000 | $132.3M | 11.9% |
| 4 | COGTCOGENT BIOSCIENCES INC | 2.4M | $90.9M | 8.2% |
| 5 | ALMSALUMIS INC | 2.8M | $79.7M | 7.2% |
| 6 | AVBPARRIVENT BIOPHARMA INC | 2.0M | $68.5M | 6.2% |
| 7 | TSHATAYSHA GENE THERAPIES INC | 9.7M | $66.0M | 5.9% |
| 8 | BIOABIOAGE LABS INC | 1.7M | $42.8M | 3.9% |
| 9 | MIRMMIRUM PHARMACEUTICALS INC | 338,900 | $39.7M | 3.6% |
| 10 | KYMRKYMERA THERAPEUTICS INC | 310,000 | $35.5M | 3.2% |
| 11 | AKTSAKTIS ONCOLOGY INC | 960,847 | $31.0M | 2.8% |
| 12 | XENEXENON PHARMACEUTICALS INC | 490,000 | $29.6M | 2.7% |
| 13 | ERASCA INCCALL | 1.3M | $23.0M | 2.1% |
| 14 | PALIPALISADE BIO INC | 10.3M | $21.5M | 1.9% |
| 15 | OCULOCULAR THERAPEUTIX INC | 2.1M | $20.4M | 1.8% |
| 16 | IRONDISC MEDICINE INC | 270,000 | $19.7M | 1.8% |
| 17 | SMMTSUMMIT THERAPEUTICS INC | 1.3M | $18.2M | 1.6% |
| 18 | PHARVARIS N V | 456,721 | $15.8M | 1.4% |
| 19 | ANLADLAI NORTYE LTD | 934,716 | $10.7M | 1% |
| 20 | DTILPRECISION BIOSCIENCES INC | 1.4M | $10.6M | 1% |
| 21 | DBVTDBV TECHNOLOGIES S A | 574,200 | $9.4M | 0.8% |
| 22 | FTHFAETH THERAPEUTICS INC | 361,010 | $9.0M | 0.8% |
| 23 | GYREGYRE THERAPEUTICS INC | 954,416 | $6.3M | 0.6% |
| 24 | TRVITREVI THERAPEUTICS INC | 315,000 | $5.9M | 0.5% |
| 25 | UNCYUNICYCIVE THERAPEUTICS INC | 1.0M | $4.7M | 0.4% |
| 26 | CNTXCONTEXT THERAPEUTICS INC | 3.0M | $1.7M | 0.2% |
| 27 | GOSSGOSSAMER BIO INC | 7.8M | $1.3M | 0.1% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.